Introduction {#s1}
============

Atrial fibrillation (AF) is the most prevalent sustained arrhythmia and its prevalence is likely to rise steeply until 2050.[@R1] Stroke and systemic embolism are among the most feared complications of AF and can be effectively tackled by anticoagulation.[@R2]

Catheter ablation is currently recommended (class IIa, level of evidence C) as an interventional alternative for the treatment of patients with AF having symptomatic recurrences despite antiarrhythmic therapy.[@R3] Over the last 13 years this has become a very commonly performed procedure for the treatment of symptomatic AF patients.[@R4]

Rigorous anticoagulation in the setting of AF catheter ablation has been demonstrated to be of prime importance. The recent large phase III trials involving the use of novel oral anticoagulants[@R5] confirmed the non-inferiority, and even superiority in some cases, of dabigatran, rivaroxaban, and apixaban compared to warfarin in AF patients. However, since a planned AF catheter ablation procedure was listed as an exclusion criteria in those trials, the efficacy and safety results cannot be extended to that setting. The 2012 Expert Consensus Statement on the management of patients with AF, by the Heart Rhythm Society, European Heart Rhythm Association, and European Cardiac Arrhythmia Society,[@R8] highlights the limited clinical experience with the new anticoagulants in AF catheter ablation. Thus, even though dabigatran is being widely used and has been in vogue longer than the other new agents, strong evidence towards its utilisation in patients undergoing AF ablation is lacking. Further, the presence of controversial results[@R9] in controlled trials with warfarin has led cardiologists to question its safety and efficacy.

We therefore aimed to systematically evaluate, using a meta-analysis, all evidence concerning the use of dabigatran versus warfarin in catheter ablation for AF. The main objectives of this study were: (1) evaluate the efficacy and safety of dabigatran compared to warfarin; (2) determine whether there were significant differences between the 110 mg twice daily and 150 mg twice daily dosages of dabigatran; and (3) study the management of periprocedural bridging anticoagulation.

Methods {#s2}
=======

Data sources and search strategy {#s2a}
--------------------------------

We performed a search on Medline (via Ovid and PubMed), Embase, and Cochrane (from inception to 13 April 2013) databases using the following search string: "atrial fibrillation" AND "ablation" AND "dabigatran".

The reference lists of the accessed full text articles were further researched for sources of potential information relevant to this analysis. Experts in the field were contacted to ensure that all important studies in this area were covered. Abstract authors in congresses were also contacted by email in order to retrieve additional information. The databases were reassessed before the completion of the manuscript to find if any of the included abstracts had been published as full text meanwhile.

Inclusion and exclusion criteria {#s2b}
--------------------------------

The population, intervention, comparison, and outcome approach was used for conducting the meta-analysis.[@R10] The population of interest included patients with AF. The intervention was catheter ablation of AF and the associated periprocedural anticoagulation. Comparisons were performed between the following groups: warfarin versus dabigatran; dabigatran 110 mg twice daily vs 150 mg twice daily. The primary outcomes were: major bleeding, thromboembolism, and all cause mortality. The presence of minor bleeding, when reported, was also assessed.

Only controlled trials (full text articles or conference abstracts) of patients undergoing catheter ablation of AF and treated either with warfarin or dabigatran before the procedure were selected.

The minimum necessary follow-up for study inclusion was until discharge after the procedure. Additionally, to be included, studies needed to provide information on assessment of all three major clinical outcome parameters: major bleeding, thromboembolism, and death.

The following exclusion criteria were defined: trials with no comparator (ie, warfarin), namely observational studies including only patients treated with dabigatran; starting of dabigatran treatment only after catheter ablation; and evaluation of efficacy restricted to laboratory or imaging end points.

To ensure that trials met the prespecified inclusion criteria, search results were reviewed by three investigators (RP, AB, BC), who needed to be in agreement for study selection.

Data extraction and presentation for the preparation of this manuscript followed the recommendations of the PRISMA group.[@R11]

Study quality was formally evaluated using the Delphi Consensus criteria for randomised controlled trials[@R12] and a modified Newcastle--Ottawa Quality Assessment Scale for Case Control Studies[@R13] by three reviewers (RP, AB, BC). An agreement, between the three reviewers was mandatory for the final classification of studies.

End point definition for meta-analysis {#s2c}
--------------------------------------

Classification of bleeding was based on previous reports and suggested recommendations.[@R14] The following end points were defined for the generation of forest plots on meta-analysis.

The primary end points were: All cause periprocedural deathThromboembolism---a composite of stroke, transient ischaemic attack (TIA), systemic or pulmonary embolism. Asymptomatic cerebral embolism detected on routine or protocol MRI or CT (ie, imaging end points with no clinical manifestation) was not included in the analysis.Major bleeding---comprising cardiac tamponade, bleeding necessitating intervention or transfusion, massive haemoptysis, haemothorax, retroperitoneal bleeding or any other life-threatening bleed leading to prolongation of hospitalisation.

Secondary end point was: Minor bleeding---defined as puncture site bleeding, thigh ecchymosis or haematoma, pericardial effusion with no haemodynamic compromise, minor gastrointestinal bleeding, epistaxis or any bleeding treated conservatively with no need for transfusion, surgery or prolonged hospitalisation.

Assessment of periprocedural bridging of anticoagulation {#s2d}
--------------------------------------------------------

The following data were extracted for assessing periprocedural bridging anticoagulation: periprocedural warfarin regimen (uninterrupted drug or discontinuation); timing of dabigatran interruption and restart; target activated clotting time (ACT).

Statistical analysis {#s2e}
--------------------

Data were pooled using random effects, according to the Mantel--Haenszel model, through Review Manager (RevMan), V.5.1. (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). The measurement of treatment effect was performed using risk ratios (RR) and 95% CIs. Pairwise comparisons were performed for all end points between patients treated with dabigatran and warfarin, and a separate sub-analysis (sensitivity analysis) was performed among patients treated with dabigatran, according to the dosage mentioned in the trials (150 mg twice daily vs 110 mg twice daily). Sensitivity analysis was also performed restricting the analysis of data to: trials whose patients were treated with uninterrupted warfarin, prospective studies, investigations published as full text articles, studies whose follow-up was at least 30 days, and studies in which five of the nine items on the Delphi Consensus criteria for randomised controlled trials and a modified Newcastle--Ottawa Quality Assessment Scale for case--control studies were deemed satisfactory.

Statistical heterogeneity on each outcome of interest was assessed and quantified using the Cochran Q test and the I^2^ statistic, respectively. The presence of publication bias was evaluated by the use of funnel plots.

Results {#s3}
=======

Search results {#s3a}
--------------

Overall, 228 entries were retrieved for title and abstract analysis. Of these, 169 were excluded as they did not meet inclusion criteria for the meta-analysis. The remaining 59 results were carefully screened, and after analysis of the full text (in the case of journal articles), only 14 studies (nine full text papers[@R9] [@R15] and five conference abstracts[@R23]) were deemed adequate for our review\'s purpose. The stepwise selection process is illustrated in [figure 1](#HEARTJNL2013304386F1){ref-type="fig"}. There was a good agreement between investigators on the inclusion of the selected trials.

![** **Flowchart diagram illustrating study selection.](heartjnl-2013-304386f01){#HEARTJNL2013304386F1}

Baseline data and the design of selected trials are summarised in [tables 1](#HEARTJNL2013304386TB1){ref-type="table"} and [2](#HEARTJNL2013304386TB2){ref-type="table"}. The final population for this meta-analysis was composed of 4782 patients (1823 treated with dabigatran and 2959 with warfarin). [Table 3](#HEARTJNL2013304386TB3){ref-type="table"} illustrates the assessment of the included studies through the Delphi criteria for randomised studies and the Newcastle--Ottawa Scale for non-randomised case--control studies.

###### 

Baseline characteristics of included studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                   Bassiouny *et al*[@R15]             Bernard *et al*[@R23]   Haines *et al*[@R16]                               Ichiki *et al*[@R24]                      Kaseno *et al*[@R17]   Kim *et al*[@R18]   Lakkireddy *et al* [@R9]                    Maddox *et al.*[@R19]   Mendoza *et al*[@R25]   Nin *et al*[@R20]         Pavaci *et al*[@R26]                 Rowley *et al*[@R27]   Snipelisky *et al*[@R21]   Yamaji *et al*[@R22]
  -------------------------------- ----------------------------------- ----------------------- -------------------------------------------------- ----------------------------------------- ---------------------- ------------------- ------------------------------------------- ----------------------- ----------------------- ------------------------- ------------------------------------ ---------------------- -------------------------- ------------------------------------------------
  Source type                      Journal article                     Conference abstract     Journal article                                    Conference abstract                       Journal article        Journal article     Journal article                             Journal article         Conference abstract     Journal article           Conference abstract                  Conference abstract    Journal article            Journal article

  Study design                     Prospective, monocentric registry   Retrospective           Multicentric, retrospective, case-match analysis   Prospective, non-randomised               Retrospective          Retrospective       Multicentric, prospective, non-randomised   Retrospective           Retrospective           Prospective, randomised   Retrospective, case-match analysis   Retrospective          Retrospective              Retrospective, non-randomised and randomised\*

  Paroxysmal AF                    57% D\                              46% D\                  53% D\                                             53%                                       83% D\                 53% D\              57% D\                                      63% D\                  NA                      76% D\                    NA                                   NA                     68% D\                     65% D\
                                   55% W                               50% W                   48% W                                                                                        55% W                  48% W               57% W                                       57% W                                           71% W                                                                                 46% W                      62% W

  Age                              58.6 D\                             62.7 D\                 60.2 D\                                            n.s.                                      59 D\                  61 D\               60.4 D\                                     62.3 D\                 62.9 D\                 61 D\                     NA\                                  63±10\                 60.6 D\                    60 D\
                                   62.7 W                              67.3 W                  59.7 W                                                                                       62 W                   61 W                60.3 W                                      62.5 W                  64.0 W                  61 W                      Case-matched                         similar                64.6 W                     61 W

  ♀ Gender                         25% D\                              NA                      26% D\                                             NA                                        25% D\                 20% D\              21% D\                                      24% D\                  10% D\                  16% D\                    NA\                                  NA                     19.4% D\                   25% D\
                                   26.6% W                                                     31% W                                                                                        21% W                  26% W               21% W                                       33% W                   12% W                   20% W                     Case-matched                                                25.6% W                    24% W

  Estimated thrombo-embolic risk   CHADS~2~\                           CHA~2~DS~2~-VASc\       CHA~2~DS~2~-VASc\                                  Values NA\                                CHADS~2~\              CHA~2~DS~2~-VASc\   CHADS~2~\                                   CHADS~2~\               CHADS~2~\               CHADS~2~\                 NA                                   CHADS~2~\              CHADS~2~\                  CHADS~2~\
                                   Score=0\                            2.00 D\                 1.6±1.3 D\                                         ns differences between treatment groups   Score=0\               1.6±1.3 D\          Score=0\                                    0.92±0.88 D\            1.32 D\                 Score ≤1\                                                      1.3±1                  0.80 D\                    Score=0\
                                   42.6% D\                            2.68 W\                 1.9±1.4 W                                                                                    61% D 45% W\           1.7±1.3 W           35% D 40% W\                                0.92±0.85 W\            1.29 W                  82% D 80% W\                                                                          1.16 W                     36% D 33% W\
                                   29.1% W\                            \                                                                                                                    Score=1\                                   Score=1\                                    CHA~2~DS~2~-VASc\                               Score=1\                                                                                                         Score=1\
                                   Score=1\                                                                                                                                                 31%D 41% W\                                43% D 41% W\                                1.73±1.45 D\                                    11% D 13% W\                                                                                                     40% D 38% W\
                                   37.0% D\                                                                                                                                                 Score ≥2\                                  Score ≥2\                                   1.69±1.33 W\                                    Score ≥2\                                                                                                        Score ≥2\
                                   41.6% W\                                                                                                                                                 8% D 14% W                                 23% D 19% W\                                \                                               4% D 11% W                                                                                                       24% D 29% W\
                                   Score ≥2\                                                                                                                                                                                           CHA~2~DS~2~-VASc\                                                                                                                                                                                            CHA~2~DS~2~-VASc\
                                   20.5% D\                                                                                                                                                                                            1.6±1.4 D\                                                                                                                                                                                                   1.8±1.6 D\
                                   29.4% W                                                                                                                                                                                             1.5±1.3 W                                                                                                                                                                                                    1.7±1.6 W

  Estimated bleeding risk          NA                                  NA                      NA                                                 NA                                        HAS-BLED\              HAS-BLED\           HAS-BLED\                                   NA                      HAS-BLED\               NA                        NA                                   NA                     NA                         NA
                                                                                                                                                                                            0.5±0.7 D\             1.0±0.9 D\          1.2±0.9 D\                                                          1.47 D\                                                                                                                                  
                                                                                                                                                                                            0.6±0.6 W              1.1±0.9 W           1.1±0.9 W                                                           1.63 W                                                                                                                                   

  LV ejection fraction             55% D\                              60% D\                  56% D\                                             NA                                        64% D\                 58% D\              56% D\                                      53% D\                  NA                      61% D\                    NA                                   NA                     NA                         60% D\
                                   55% W                               58% W                   57% W                                                                                        63% W                  57% W               56% W                                       54% W                                           62% W                                                                                                            60% W

  CKD/kidney function              Creat\                              Creat\                  Creat clearance\                                   NA                                        Creat clearance\       Creat\              CKD\                                        Creat\                  NA                      Creat\                    NA                                   NA                     NA                         Exclusion of patients with renal clearance\
                                   0.9 mg/dL D\                        1.0 mg/dL D\            93 ml/min D\                                                                                 97 ml/min D\           0.9 mg/dL D\        1% D\                                       1.0 mg/dL D\                                    0.9 mg/dL D\                                                                                                     \< 30 mL/min
                                   0.9 mg/dL W                         1.3 mg/dL W             93 ml/min W                                                                                  98 ml/min W            0.9 mg/dLW          2% W                                        1.1 mg/dL W                                     0.9 mg/dL W                                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The first 291 patients were assigned to interrupted and non-interrupted warfarin in a non-randomised fashion and the last 212 patients were randomised to either uninterrupted warfarin or dabigatran.

AF, atrial fibrillation; CKD, chronic kidney disease; Creat, creatinine; D, dabigatran; LV, left ventricle; NA, not available; W, warfarin.

###### 

Description of periprocedural anticoagulation

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                 Bassiouny *et al*[@R15]                                   Bernard *et al*[@R23]   Haines *et al*[@R16]                 Ichiki *et al*[@R24]   Kaseno *et al*[@R17]      Kim *et al*[@R18]        Lakkireddy *et al*[@R9]   Maddox *et al*[@R19]                 Mendoza *et al*[@R25]                          Nin *et al* [@R20]                           Pavaci *et al*[@R26]   Rowley *et al*[@R27]      Snipelisky *et al.* [@R21]       Yamaji *et al*[@R22]
  ---------------------------------------------- --------------------------------------------------------- ----------------------- ------------------------------------ ---------------------- ------------------------- ------------------------ ------------------------- ------------------------------------ ---------------------------------------------- -------------------------------------------- ---------------------- ------------------------- -------------------------------- --------------------------------------------------------
  Patients treated with dabigatran               376                                                       155                     222                                  30                     110                       191                      145                       212                                  60                                             45                                           27                     113                       31                               106

  Dabigatran dosage                              150 mg twice daily                                        NA                      150 mg twice daily\*                 NA                     110 mg twice daily        150 mg twice daily       150 mg twice daily        150 mg twice daily                   150 mg twice daily                             110 mg twice daily                           NA                     NA                        150 mg twice daily               110 mg twice daily in 36\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               150 mg twice daily in 70

  Timing of first held dose of dabigatrain       Morning of the day of the procedure or the night before   24 h                    ≤12 h in 35\                         Morning of procedure   Morning of procedure      Night before procedure   Morning of procedure      Uninterrupted                        Morning of procedure                           Morning of the day before procedure          NA                     Day before procedure      Morning of procedure             Morning of the day of the procedure
                                                                                                                                   12--24 h in 29\                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                   24--48 h in 102\                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                   \>48 h in 18\                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                   Unknown in 18                                                                                                                                                                                                                                                                                                                                               

  Time interval for restarting after procedure   After arousal from anesthesia/sedation                    Within 24 h             ≤6 h in 116\                         NA                     Morning after procedure   4 h                      3 h                       Uninterrupted                        Immediately after sheath removal (144.3 min)   4 h after haemostasis at the puncture site   NA                     \> 24 h (day following)   Evening of procedure             Single dose, 3 h after the completion of the procedure
                                                                                                                                   6--24 h in 83\                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                   \>24 h in 1\                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                   Unknown in 2                                                                                                                                                                                                                                                                                                                                                

  Patients treated with warfarin                 623                                                       44                      222                                  180                    101                       572                      145                       251                                  58                                             45                                           27                     169                       125                              397

  Timing of first held dose of warfarin          Uninterrupted                                             Uninterrupted           ≤12 h in 74\                         Uninterrupted          Uninterrupted             Uninterrupted            Uninterrupted             Uninterrupted                        Uninterrupted                                  Morning of the day before procedure          Uninterrupted          Day before procedure      Evening prior to the procedure   Uninterrupted in 203 patients.\
                                                                                                                                   12--24 h in 88\                                                                                                                                                                                                                                                                                                                                             Interrupted 48 h before in 194
                                                                                                                                   24--48 h in 15\                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                   \>48 h in 25                                                                                                                                                                                                                                                                                                                                                

  Timing for restarting warfarin                 Uninterrupted                                             Uninterrupted           Day of the procedure                 Uninterrupted          Uninterrupted             Uninterrupted            Uninterrupted             Uninterrupted                        Uninterrupted                                  4 h after haemostasis at the puncture site   Uninterrupted          Day after procedure       Evening of procedure             Day after procedure in patients who stopped warfarin

  Target ACT (seconds) during procedure          350--450                                                  NA                      300--350 at least                    NA                     300--350                  300--350                 300--400                  \>350--400                           300--350                                       300--400                                     250--300               NA                        \>350                            300--350

  Follow-up duration                             1 month                                                   1 month                 Periprocedural/ hospital discharge   NA                     At least 2 months         3 months                 30 days                   Periprocedural/ hospital discharge   1 month                                        2 weeks                                      NA                     30 days                   1 week                           3 months
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Except for one elderly patient who took the 110 mg twice daily dose.

ACT, activated clotting time; NA, not available.

###### 

Assessment of the quality of included studies: Delphi criteria for randomised studies and Newcastle--Ottawa Scale for non-randomised case-controls studies

  Study                      Assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Classification\*
  -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------
  Bassiouny *et al*[@R15]    Adequate case definition; consecutive series of cases; adequate information concerning the selection and definition of controls; groups controlled for baseline characteristics; ascertainment of outpatient exposure to anticoagulants based on medical records both for cases and controls, and laboratory data for warfarin; patients not blinded to case-control status.                                                                                                                                                                                                                                                                                                                           Attributable stars: 7
  Bernard *et al*[@R23]      Adequate case definition; consecutive series of cases; controls were slightly older (3 years in average), had higher creatinine values (1.3 vs 1.0 mg/dL) and a higher CHA~2~DS~2~-VASc (2.68 vs 2.00); information concerning the selection and definition of controls.                                                                                                                                                                                                                                                                                                                                                                                                                               Attributable stars: 3
  Haines *et al*[@R16]       Adequate case definition; consecutive series of cases; hospital controls, obtained by computer list generation; groups controlled for most baseline characteristics, except for slight differences in congestive heart failure, more prevalent in the dabigatran group, and previous stroke, more prevalent in the warfarin group; a higher utilisation of concomitant aspirin was observed in dabigatran patients and heparin/low molecular weight heparin was more used in the warfarin treatment arm; ascertainment of outpatient exposure to anticoagulants based on medical records both for cases and controls, and laboratory data for warfarin; patients not blinded to case-control status.   Attributable stars: 6
  Ichiki *et al*[@R24]       Adequate case definition; consecutive series of cases; adequate information concerning the selection and definition of controls; information concerning the selection and definition of controls.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Attributable stars: 4
  Kaseno *et al*[@R17]       Adequate case definition; information concerning the selection and definition of controls; hospital controls; slight difference in baseline age (warfarin patients 3 years older), larger left atrial diameter (4 mm difference in average) and higher prevalence of persistent AF in the warfarin group, requiring additional substrate modification; ascertainment of outpatient exposure to anticoagulants based on medical records both for cases and controls, and laboratory data for warfarin; patients not blinded to case-control status.                                                                                                                                                     Attributable stars: 4
  Kim *et al*[@R18]          Adequate case definition; consecutive series of cases; adequate information concerning the selection and definition of controls; groups controlled for baseline characteristics, except for previous stroke, that was slightly more prevalent in the warfarin group; ascertainment of outpatient exposure to anticoagulants based on medical records both for cases and controls, and laboratory data for warfarin; close monitoring of all patients during the 3 month follow-up period after the procedure; patients not blinded to case-control status.                                                                                                                                             Attributable stars: 6
  Lakkireddy *et al*[@R9]    Adequate case definition; consecutive series of cases in the dabigatran treatment arm; controls matched for age, sex and type of AF; groups controlled for baseline characteristics; ascertainment of outpatient exposure to anticoagulants based on medical records both for cases and controls, and laboratory data for warfarin; patients not blinded to case-control status.                                                                                                                                                                                                                                                                                                                       Attributable stars: 6
  Maddox *et al*[@R19]       Adequate case definition; consecutive series of cases; adequate information concerning the selection and definition of controls; groups controlled for most baseline characteristics, except for a slightly higher percentage of males in the dabigatran group; ascertainment of outpatient exposure to anticoagulants based on medical records both for cases and controls, and laboratory data for warfarin; patients not blinded to case-control status.                                                                                                                                                                                                                                            Attributable stars: 6
  Mendoza *et al*[@R25]      Adequate case definition; consecutive series of cases; hospital controls; information concerning the selection and definition of controls.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Attributable stars: 4
  Nin *et al*[@R20]          Randomisation performed; groups similar at baseline; eligibility criteria specified; point estimates and measures of variability presented for outcome measures; analysis of end points performed on an intention-to-treat basis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Positive Delphi criteria: 5
  Pavaci *et al*[@R26]       Adequate case definition; consecutive series of cases treated with dabigatran; case matched hospital controls considering age, gender, body mass index, creatinine values, left atrium dimensions and type of arrhythmia; information concerning the selection and definition of controls.                                                                                                                                                                                                                                                                                                                                                                                                             Attributable stars: 4
  Rowley *et al*[@R27]       Adequate case definition; series of cases treated with dabigatran, no information if the patients were consecutive; no information concerning the selection and definition of controls; similar age and CHADS~2~ score among treatment groups.                                                                                                                                                                                                                                                                                                                                                                                                                                                         Attributable stars: 3
  Snipelisky *et al*[@R21]   Adequate case definition; consecutive series of cases; adequate information concerning the selection and definition of controls; groups controlled for baseline characteristics, except for higher prevalence of persistent AF in the warfarin group; ascertainment of outpatient exposure to anticoagulants based on medical records both for cases and controls, and laboratory data for warfarin; patients not blinded to case-control status; all patients had evidence for a completed medication profile with reconciliation.                                                                                                                                                                    Attributable stars: 7
  Yamaji *et al*[@R22]       Adequate case definition; consecutive series of patients assigned to treatment groups in a non-randomised fashion in the first part of the study and with randomisation to dabigatran or uninterrupted warfarin in the last 212 patients; adequate information concerning the selection and definition of controls; groups controlled for baseline characteristics; ascertainment of outpatient exposure to anticoagulants based on medical records both for cases and controls, and laboratory data for warfarin; close monitoring of all patients during the 3-month follow-up period after the procedure; patients not blinded to case-control status.                                              Attributable stars: 7

\*Number of criteria met out of a total of nine.

AF, atrial fibrillation.

The observed I^2^ values showed a low to moderate heterogeneity in the main end point comparisons (I^2^=0 for stroke and 41% for major bleeding).

Efficacy and safety of dabigatran versus warfarin {#s3b}
-------------------------------------------------

The main efficacy and safety outcomes (prevention of embolism and major bleeding) observed in the comparison between dabigatran and warfarin are displayed in [figure 2](#HEARTJNL2013304386F2){ref-type="fig"} and [table 4](#HEARTJNL2013304386TB4){ref-type="table"}. The funnel plot to ascertain publication bias is shown in [figure 3](#HEARTJNL2013304386F3){ref-type="fig"}.

###### 

Comparison of endpoints across studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                     Bassiouny *et al*[@R15]      Bernard *et al* [@R23]   Haines *et al*[@R16]            Ichiki *et al*[@R24]     Kaseno *et al*[@R17]   Kim *et al*[@R18]         Lakkireddy *et al*[@R9]   Maddox *et al*[@R19]         Mendoza *et al*[@R25]   Nin *et al* [@R20]               Pavaci *et al*[@R26]   Rowley *et al.*[@R27]                          Snipelisky *et al*[@R21]   Yamaji *et al*[@R22]
  ------------------ ---------------------------- ------------------------ ------------------------------- ------------------------ ---------------------- ------------------------- ------------------------- ---------------------------- ----------------------- -------------------------------- ---------------------- ---------------------------------------------- -------------------------- -------------------------
  Minor bleeding     7/376 D\                     1/155 D\                 4/ 222 D\                       NA                       5/110 D\               5/191 D\                  12/145 D\                 1/212 D\                     1/60 D\                 9/45 D\                          2/27 D\                5/113 D\                                       6/31 D\                    2/106 D\
                     16/623 W\                    2/44 W                   2/ 222 W\                                                11/101 W\              19/572 W\                 8/145 W\                  3/251 W\                     1/58 W\                 20/45 W\                         4/27 W\                33/169 W\                                      21/125 W\                  11/397 W\
                     Groin haematoma\                                      Minor bleeding complications\                            Groin haematoma\       Groin haematoma\          Groin haematoma\          Groin haematoma\             Groin haematoma\        Rebleeding from puncture site\   Groin haematoma\       Non-life threatening vascular complications\   Haematoma\                 Groin haematoma\
                     5/ 376 D\                                             2/ 222 D\                                                5/110 D\               4/191 D\                  6/145 D\                  1/212 D\                     1/58 W\                 9/45 D\                          2/27 D\                5/113 D\                                       1/31 D\                    1/106 D\
                     10/ 623 W\                                            1/ 222 W\                                                11/101 W               19/572 W\                 5/145 W\                  2/251 W\                     GI bleed\               20/45 W                          4/27 W                 33/169 W                                       4/125 W\                   4/397 W\
                     GI bleed\                                             Vascular complication\                                                          PEff without tamponade\   PEff without tamponade\   Minor haemoptysis\           1/60 D                                                                                                                         Rebleeding\                PEff without tamponade\
                     1/376 D\                                              2/222 D\                                                                        1/191 D                   6/145 D\                  1/251 W                                                                                                                                                     5/31 D\                    1/106 D\
                     2/623 W\                                              1/222 W                                                                                                   4/145 W                                                                                                                                                                               10/125 W\                  7/397 W
                     Minor haemoptysis\                                                                                                                                                                                                                                                                                                                                    Ecchymosis\                
                     1 /623 W Epistaxis1/623 W\                                                                                                                                                                                                                                                                                                                            7/125 W                    
                     PEff without tamponade\                                                                                                                                                                                                                                                                                                                                                          
                     1/376 D\                                                                                                                                                                                                                                                                                                                                                                         
                     2/623 W                                                                                                                                                                                                                                                                                                                                                                          

  Major bleeding     4/376 D\                     2/155 D\                 3/222 D\                        4/30 D\                  0/110 D\               4/191 D\                  9/145 D\                  1/212 D\                     0                       0                                0                      0/113 D\                                       0                          0/106 D\
                     8/623 W\                     2/44 W                   3/222 W\                        4/180 W\                 2/101 W\               12/572 W\                 1/145 W\                  3/251 W\                                                                                                     1/169 W\                                                                  4/397 W\
                     PEff with need of pct\                                PEff with need of pct\          PEff with need of pct\   Cardiac tamponade\     Cardiac tamponade\        Cardiac tamponade\        Cardiac tamponade\                                                                                           Retroperitoneal bleed\                                                    Cardiac tamponade\
                     3/ D\                                                 2/222 D\                        4/30 D\                  2/101 W                2/191 D\                  9/145 D\                  1/212 D\                                                                                                     1/169 W                                                                   4/397 W
                     7/ W\                                                 2/222 W\                        4/180 W                                         7/572 W\                  1/145 W                   2/251 W\                                                                                                                                                                               
                     Haemoptysis\*\                                        Other major bleeding\                                                           Vascular complications\                             Retroperitoneal haematoma\                                                                                                                                                             
                     1/ W\                                                 1/222 D\                                                                        2/191 D\                                            1/251 W                                                                                                                                                                                
                     Cerebral bleeding\                                    1/222 W                                                                         5/572 W\                                                                                                                                                                                                                                   
                     1/ D†                                                                                                                                 \                                                                                                                                                                                                                                          

  Thrombo-embolism   1/376 D\                     0                        2/222 D ‡\                      0                        0                      0                         3/145 D\                  1/212 D\                     0/60 D\                 0/45 D\                          1/27 D\                2/113 D\                                       0                          0
                     1/623 W\                                              0/222 W\                                                                                                  0/145 W\                  0/251\                       1/58 W\                 1/45 W\                          0/27 W\                2/169 W\                                                                  
                     Stroke\                                               Stroke\                                                                                                   Stroke or TIA\            TIA\                         Stroke\                 Mesenteric thrombosis\           Stroke\                Stroke\                                                                   
                     1/623 W\                                              1/222 D\                                                                                                  3/145 D                   1/212 D                      1/58 W                  1/45 W                           1/27 D                 1/113 D\                                                                  
                     Pulmonary embolism\                                   TIA\                                                                                                                                                                                                                                             1/169 W\                                                                  
                     1/376 D                                               1/222 D                                                                                                                                                                                                                                          TIA\                                                                      
                                                                                                                                                                                                                                                                                                                            1/113 D\                                                                  
                                                                                                                                                                                                                                                                                                                            Pulmonary embolism\                                                       
                                                                                                                                                                                                                                                                                                                            1/169 W                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Requiring transfusion.

†Patient with a cerebral cavernous malformation.

‡The patients with stroke stopped dabigatran 36 h before the procedure and the patient with TIA restarted the drug only 17 h after the procedure.

D, dabigatran; GI, gastrointestinal; NA, data not available; pct,  pericardiocentesis; PEff, pericardial effusion; punct, puncture; TIA,  transient ischaemic attack; W, warfarin.

![Main efficacy and safety outcomes of the comparison of dabigatran versus warfarin among patients with atrial fibrillation treated with catheter ablation. (A) Stroke and thromboembolism. (B) Major bleeding. M-H, Mantel--Haenszel.](heartjnl-2013-304386f02){#HEARTJNL2013304386F2}

![Funnel plots representing the studies used in the assessment of: (A) stroke and thromboembolism; and (B) major bleeding. The inverted and symmetrical funnel aspect can be observed for the assessed end points, with 95% of the studies lying within the confidence limit lines. This suggests that publication bias is not present among the selected studies for the meta-analysis.](heartjnl-2013-304386f03){#HEARTJNL2013304386F3}

### Death and thromboembolism {#s3b1}

No deaths were observed in any of the intervention groups. Thromboembolic events were reported in only 0.31% of patients (15 out of 4782) and no significant differences were found between dabigatran and warfarin: 0.55% vs 0.17%, respectively (RR=1.78, 95% CI 0.66 to 4.80; p=0.26).

### Major bleeding {#s3b2}

Among all 14 studies, 67 events (accounting for an overall 1.40% incidence) of major bleeding were reported, with no significant differences observed between the two treatment arms (1.48% dabigatran vs 1.35% warfarin; RR=1.07, 95% CI 0.51 to 2.26; p=0.86).

### Minor bleeding {#s3b3}

Information on minor bleeding was not reported in one of the selected studies.[@R24] In the remaining, comprising 4572 participants, 210 minor bleeding events (overall incidence 4.59%; 3.35% dabigatran vs 5.40% warfarin) were reported, with a relative risk reduction of 35% (95% CI 7 to 55%; p=0.02) in favour of dabigatran ([figure 4](#HEARTJNL2013304386F4){ref-type="fig"}).

![Incidence of minor bleeding among patients treated with dabigatran or warfarin. (A) Forest plot. (B) Funnel-plot. M-H, Mantel--Haenszel.](heartjnl-2013-304386f04){#HEARTJNL2013304386F4}

### Sensitivity analysis {#s3b4}

Sensitivity analysis confirmed the lack of interference of uninterrupted warfarin, prospective studies, full text articles, studies whose follow-up was at least 30 days, and higher methodological quality studies ([figures 5](#HEARTJNL2013304386F5){ref-type="fig"}[](#HEARTJNL2013304386F6){ref-type="fig"}--[7](#HEARTJNL2013304386F7){ref-type="fig"}) in the overall results concerning the main end points: stroke and thromboembolism and major bleeding. However, as regards minor bleeding these analyses suggested a lack of significant differences.

![Forest plot illustrating the sensitivity analysis restricting data to: (A) trials whose patients were treated uninterrupted warfarin; and (B) prospective studies. M-H, Mantel--Haenszel.](heartjnl-2013-304386f05){#HEARTJNL2013304386F5}

![Forest plot illustrating the sensitivity analysis restricting data to: (A) investigations published as full text articles; and (B) studies whose follow-up was at least 30 days. M-H, Mantel--Haenszel.](heartjnl-2013-304386f06){#HEARTJNL2013304386F6}

![Forest plot illustrating the sensitivity analysis restricting data to higher quality full text articles (Delphi criteria or Newcastle--Ottawa Scale ≥5). M-H, Mantel--Haenszel.](heartjnl-2013-304386f07){#HEARTJNL2013304386F7}

Effect of dabigatran dosage: 150 mg twice daily vs 110 mg twice daily {#s3c}
---------------------------------------------------------------------

Information on the dose of dabigatran used was available for 1392 patients (155 with 110 mg twice daily and 1237 with 150 mg twice daily). No significant differences were found between the two dosage groups (110 mg twice daily vs 150 mg twice daily, respectively) regarding major bleeding (0% vs 1.62%; RR=0.19, 95% CI 0.01 to 3.18; p=0.25) and thromboembolism (0% vs 0.40%; RR=0.72, 95% CI 0.04 to 12.98; p=0.82). Concerning minor bleeding, more events were observed with the 110 mg twice daily dosage: 9.03% vs 2.51% (RR=3.60, 95% CI 1.96 to 6.62; p\<0.0001).

Management of periprocedural anticoagulation {#s3d}
--------------------------------------------

The different periprocedural regimens used in patients treated with dabigatran are displayed in [table 2](#HEARTJNL2013304386TB2){ref-type="table"}. The timing of the first withheld dose ranged from the morning of procedure (in four studies) to 48 h before; the time interval for restarting ranged from 3--4 h (in six studies) to 24 h after ablation. In one study, uninterrupted dabigatran was used.[@R19]

One third of all strokes or TIAs were associated with suspension of dabigatran for ≥24 h before procedure (one stroke in Haines *et al*[@R16] and one stroke and one TIA in Rowley *et al*[@R27]). Additionally, of all stroke and TIA in patients treated with dabigatran, 50% was related to a later timing (≥12 h) for restarting the drug post-procedure (two strokes and two TIAs[@R16] [@R27]). On the other hand, a higher incidence of major bleeding was reported by Lakkireddy *et al*,[@R9] where dabigatran was stopped only in the morning of the procedure and restarted 3 h post-procedure. Albeit suggesting a similar safety and efficacy profile, with non-inferiority versus warfarin, data concerning uninterrupted dabigatran results exclusively from one trial.[@R19]

Among the patients of the warfarin group, safety and efficacy outcomes were similar irrespective of whether warfarin was continued or interrupted.

In addition, target ACT during procedure was 300--350 s in most studies, \>350 s in five,[@R9] [@R15] [@R19] and 250--300 s in one.[@R26] A higher value for target ACT[@R9] [@R15] [@R19] was not associated with a lower incidence of thromboembolic events. Furthermore, in the investigation by Lakkireddy *et al*[@R9] a higher rate of cardiac tamponade in dabigatran treated patients (9/145) was observed. Importantly, a 3.7% rate of stroke was observed in the single study featuring a target ACT of 250--300 s.[@R26] However, due to the low number of participants, the possibility of a false positive association cannot be excluded.

Discussion {#s4}
==========

The low rate of thromboembolic complications and major bleeding seen with dabigatran (which was also similar to that observed with warfarin) seems to provide favourable support for its use, as an alternative to warfarin, in the setting of catheter ablation of AF. These results add important information on the use of dabigatran in this setting. They also serve to potentially alleviate some of the concerns raised by the rather unfavourable results in earlier studies (2.1% stroke or TIA and 6.2% major bleeds),[@R9] suggesting that dabigatran significantly increased the risk of bleeding or thromboembolic complications compared with uninterrupted warfarin therapy.

A very low rate of stroke and thromboembolic events was found in this meta-analysis among patients treated with dabigatran (0.55%), similar to what has been found in a recent analysis of Medicare beneficiaries (0.6--0.9%).[@R28] A lower, but not significantly different, prevalence of embolism was found in the warfarin arm of this meta-analysis (0.17%), composed mainly of patients with uninterrupted treatment. This value is similar to the one described by Hussein  *et al*[@R29] in patients with uninterrupted warfarin. Therefore, we think that despite showing similar results compared to warfarin in this meta-analysis (and presenting values for thromboembolic complications similar to what has been reported in large registries of patients using anti-vitamin K agents[@R28]), validation of these results in future randomised controlled trials with blinded analysis may be justified. Furthermore, the use of uninterrupted dabigatran may also merit assessment, taking into account the promising results of the recently available study with this treatment regimen.[@R19]

The proportion of patients referred for AF ablation who are on longstanding dabigatran therapy is progressively increasing. This is likely to pose new challenges for the practising cardiologist, including the question of performing the procedure without discontinuation of dabigatran. The pooled data in this study from a large sample of patients provides an opportunity to address some of these issues.

In this meta-analysis comprising 14 controlled trials, dabigatran performed similarly to warfarin with regard to major bleeding and thromboembolism. Moreover, no deaths were observed in any of the treatment strategies. These results are in agreement with the favourable profile that was observed in an early observational non-controlled trial by Winckle *et al.*[@R30] Furthermore, a recent analysis of the US Food and Drug Administration (FDA) Mini-Sentinel database for the period from 19 October 2010 (the date of dabigatran approval) to 31 December 2011, found that bleeding rates associated with dabigatran use during the period of interest did not appear to be higher than those associated with warfarin.[@R31]

Though the present analysis suggests a lower rate of minor bleeding with dabigatran, there were pronounced differences in the reporting of this end point across the different studies. Furthermore, on sensitivity analysis these results did not remain significant. Thus, while this result needs to be interpreted with caution, it seems, that at the very least, dabigatran is unlikely to be inferior to warfarin in this regard.

No significant differences in major bleeding and thromboembolism were observed between the two assigned dabigatran dosages. However, the low number of patients in each group (resulting from under-reporting of the dosage used in most selected studies), and the low rate of observed events, limit the extent to which firm conclusions can be drawn. The suggestion of less frequent minor bleeding with the 150 mg twice daily dosage is hard to interpret due to the differences in reporting of this end point and in sample size.

The various transition regimens used in patients treated with dabigatran, and the low number of observed events in each of those, renders difficult the task of establishing an ideal transition regimen in this setting. However, the great inter- and sometimes intra-study variability notwithstanding, certain factors are likely to be important for decision making.

The timing for drug interruption before the procedure must take into account the patient\'s renal function, as 80% of the drug is excreted by this pathway.

In patients with normal renal clearance, the best option may be drug suspension on the morning of the procedure, or the night before, but always \<24 h before the procedure.

If renal function is compromised, the drug should probably be interrupted sooner, depending on the degree of renal dysfunction.

There may be a rationale for restarting dabigatran 3--4 h after assuring haemostasis, considering its short half-life and rapid onset of action.

The target ACT during catheter ablation in patients treated with dabigatran should be between 300--350 s (similar to warfarin), as no additional benefits were found for higher values.

Finally, as there seems to be no inherent advantage of any of the studied dabigatran dosages, the creatinine clearance and bleeding risk (HAS-BLED score) should be taken into account for deciding the dosage to be used.

Limitations {#s5}
===========

Important strengths of this study include the consistent reporting for thromboembolism (almost absent heterogeneity, I^2^=0%) across studies. However, there are certain limitations, inherent to any meta-analysis.

First, heterogeneity was observed regarding major bleeding (I^2^=41%; moderate heterogeneity). This may be explained by the pronounced diversity in ablation strategy, anticoagulation regimen, intraprocedural use of heparin, and follow-up between the incorporated studies. However, heterogeneity was low (I^2^=12%) in the sensitivity analysis including only higher methodological quality studies, which confirms the small and similar incidence of major bleeding in both treatment arms already suggested by the forest plot that included all studies.

Secondly, as already highlighted, certain comparisons are limited by the low number of subjects and low event rates.

Thirdly, in some cases of abstract related data, even with the best attempts to gather information by directly contacting the authors, some data remained incomplete. However, these were mainly with regard to minor bleeding (a secondary end point) and details concerning periprocedural drug transition; hence, missing data are unlikely to have significantly affected the primary results of the analysis.

Fourthly, only a minority of trials was randomised or prospective and a blinded analysis and/or central adjudication of end points was performed in none (ie, the higher level of data quality). Therefore, these data must be considered preliminary and interpreted with some caution.

Conclusions {#s6}
===========

The rate of thromboembolic complications and/or major bleeding in patients on dabigatran undergoing AF catheter ablation is low and similar to that seen with warfarin.

These results may suggest the feasibility and safety of AF catheter ablation in patients regularly treated with dabigatran. However, further prospective and randomised studies are still necessary to confirm these findings and clarify which periprocedural regimen can minimise the risk of thromboembolic complications with dabigatran.
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